Mavacamten: A Game Changer For Patients With HCM

Hypertrophic cardiomyopathy (HCM) causes thickening of the heart muscle, left ventricular stiffness, mitral valve changes and cellular changes. For many years, management of this condition was surgery or alcohol ablation. Mavacamten is the first FDA approved drug to help treat patients with HCM. Drs. Steven Nissen and Milind Desai talk about this novel treatment option and the benefits of being treated by a specialized center.